Special Issue

Novel Biomarkers in Translational Medicine of Chronic and Autoimmune Diseases

Message from the Guest Editors

Inflammation is a normal physiological defence against pathogen infection and tissue damage and guickly ends under normal circumstances. However, in many chronic conditions, the inflammatory response continues and leads to significant tissue/organ damage. Chronic diseases are multifactorial diseases and considered a serious public health problem. The immune system plays a central role in many processes involving chronic diseases and subsequently cancer. New therapies have been proposed with potential positive impacts for patients, minimising morbidity and mortality. The aim of this Special Issue is to invite original research articles, notable clinical findings, and review articles that present and discuss the advancement of research and innovative therapies involving chronic diseases, the regulation of inflammation in the pathology and treatment of autoimmune diseases, the relationship between inflammation and cancer, the latest research about the immune system and chronic diseases, and advances in genetics and molecular diagnostics.

Guest Editors

Dr. Umberto Basile

Head of Clinical Pathology Unit, Hospital "Santa Maria Goretti" ASL Latina, Latina, Italy

Prof. Dr. Ettore Domenico Capoluongo

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, UNIVERSITA' DEGLI STUDI FEDERICO II, Facoltà di Medicina e Chirurgia "Federico II", Napoli, Italy

Deadline for manuscript submissions

closed (10 January 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/78704

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

